We are live on ! Find out more
IMPL

Impel Pharmaceuticals Inc. Common Stock
IMPL

Delisted

IMPL was delisted on the 15th of December, 2023.

Back to rankings

2 hedge funds and large institutions have $341K invested in Impel Pharmaceuticals Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

94% less funds holding

Funds holding: 32 → 2 (-30)

95% less capital invested

Capital invested by funds: $7.35M → $341K (-$7.01M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 30

Holders
2
Holders Change
-30
Holders Change %
-93.75%
% of All Funds
0.03%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
–
Increased
–
Reduced
–
Closed
30
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
KKRC
Kohlberg Kravis Roberts & Co
New York
-$1.78M
2
NA
NVP Associates
California
-$1.32M
3
5VM
5AM Venture Management
California
-$1.24M
4
VC
Vivo Capital
California
-$1.24M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$217K
Name Holding Trade Value Shares
Change 		Change in
Stake
VP
1
venBio Partners
California
$341K – – –
DJSG
2
D.J. St. Germain
Massachusetts
$185 – – –
KKRC
3
Kohlberg Kravis Roberts & Co
New York
– -$1.78M -4,135,971 Closed
NA
4
NVP Associates
California
– -$1.32M -3,077,198 Closed
5VM
5
5AM Venture Management
California
– -$1.24M -2,884,791 Closed
VC
6
Vivo Capital
California
– -$1.24M -2,884,789 Closed
Vanguard Group
7
Vanguard Group
Pennsylvania
– -$217K -505,231 Closed
LM
8
Lasry Marc
– -$97.1K -225,874 Closed
DA
9
DCF Advisers
Connecticut
– -$76.8K -178,500 Closed
Geode Capital Management
10
Geode Capital Management
Massachusetts
– -$74.1K -172,218 Closed
Bank of New York Mellon
11
Bank of New York Mellon
New York
– -$15.2K -35,301 Closed
State Street
12
State Street
Massachusetts
– -$10.8K -25,200 Closed
BlackRock
13
BlackRock
New York
– -$9.73K -22,635 Closed
Millennium Management
14
Millennium Management
New York
– -$9.24K -21,485 Closed
XT
15
XTX Topco
Cayman Islands
– -$9.13K -21,222 Closed
TSS
16
Two Sigma Securities
New York
– -$8.8K -20,462 Closed
MP
17
McDonald Partners
Ohio
– -$8.34K -19,400 Closed
EP
18
EPIQ Partners
Minnesota
– -$7.02K -16,325 Closed
VF
19
Virtu Financial
New York
– -$7K -16,112 Closed
RJA
20
Raymond James & Associates
Florida
– -$6.24K -14,500 Closed
CAPTRUST Financial Advisors
21
CAPTRUST Financial Advisors
North Carolina
– -$6.2K -14,407 Closed
BJL
22
Brighton Jones LLC
Washington
– -$6.08K -14,145 Closed
Northern Trust
23
Northern Trust
Illinois
– -$5.68K -13,218 Closed
TRCT
24
Tower Research Capital (TRC)
New York
– -$3.41K -7,936 Closed
LC
25
Lindbrook Capital
California
– -$1.31K -3,056 Closed
1
2

IMPL Hedge Fund Activity: Q4 2023 in Review

2 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q4 2023, worth a combined $341K — down 95% from $7.35M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of IMPL and 0 opened new positions — a net loss of 30 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Kohlberg Kravis Roberts & Co, exiting entirely with an estimated $1.78M sold.

  • 2 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q4 2023, down from 32 in Q3 2023.
  • Funds reported $341K of Impel Pharmaceuticals Inc. Common Stock stock for Q4 2023, down 95% quarter-over-quarter.
  • 0 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q4 2023 and 30 closed out, a net change of -30 holders.
  • The largest Impel Pharmaceuticals Inc. Common Stock seller in Q4 2023 was Kohlberg Kravis Roberts & Co, an estimated $1.78M sold.

Based on aggregated 13F filings for Q4 2023.